Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

) of Aloxi in this pediatric population was consistent with that in adults. There were no cardiac safety concerns or serious treatment related adverse events.

Dacogen(R) for Injection

Study of Response to Dacogen in Older Patients Diagnosed with Acute Myelogenous Leukemia (AML)

The impact of Dacogen on the survival of older patients with AML was presented in a poster discussion on Monday, June 4, 2007. A total of 33 patients meeting the WHO definition of AML ( greater than or equal to 20% bone marrow blasts) who had been treated with Dacogen as front-line therapy on either the randomized Phase 3 study in patients with myelodysplastic syndromes, or on two consecutive studies of Dacogen, alone or in combination with valproic acid were evaluated retrospectively. Response to therapy was assessed by the International Working Group criteria. In the 33 patients treated with intravenous Dacogen (100-150 mg/m2/course), an overall response rate ranging from 50-57% was observed across the three clinical trials with complete and partial response rates of 24% and 6%, respectively, and hematologic improvement and marrow complete response rates of 15% and 6%, respectively. The median survival for the Dacogen treated patients was 12.6 months, the median duration of response was 8.8 months, and 1- and 2-year survival rates were 51% and 26%, respectively. Regardless of blast percentage, cytogenetics, or age, responses were observed in all risk groups. Additionally, the survival of the Dacogen treated group compared favorably to that of 330 patients with AML (over 60 years of age) given standard induction therapy containing cytarabine and treated in the same time-period. Non-hematologic adverse events included myocardial infarction, dyspnea, hyperbilirubinemia, dehydration, syncope, headache, and hypokalemia.

Phase 1 Study of Dacogen in Patients with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Interim results of two consecutive phase 1 st
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:4/17/2015)... April 17, 2015 ASSESS shows ...   is a viable alternative to tumour biopsy   ... all patients with advanced NSCLC   AstraZeneca today ... plasma circulating tumour DNA (ctDNA) testing for epidermal growth factor ... non-small cell lung cancer (NSCLC) in clinical practice. [ ...
(Date:4/17/2015)... YORK , April 17, 2015  Over the next ... to continue to grow, with ArcView predicting that 14 more ... legalize medical marijuana. The U.S. market for legal cannabis grew ... billion in 2013. Analysts project the market could grow more ... assuming more states soften their stance on marijuana. ...
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
(Date:4/18/2015)... 18, 2015 Review of Ophthalmology magazine ... ‘Strategies for Success’ program for cataract surgeons attending the ... San Diego, where eye surgeon Jeffrey L. Martin, MD ... event. Dr. Martin is the Managing Partner of North ... chose Dr. Martin to lead this year’s discussion on ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 On April 14th, ... Threat Report , which they say, “exposes a tactical shift ... new malware variants were introduced in 2014 - almost a ... Zero Day threats to be identified and patched by prominent ... abundantly clear that doing business in a digital world can ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... is available in French . , Pediatric ... a massive boost today, following the Cole Foundation,s announcement that ... 10 Universit de Montral and four McGill University young scientists. ... and lymphomas in people under the age of 25, and ...
... , TUESDAY, May 17 (HealthDay News) -- A ... affect production of the pregnancy hormone progesterone and may be ... The Johns Hopkins University team looked at more than ... and identified nine who had the variation of the scavenger ...
... four years of remarkable progress including pioneering discoveries ... Medical Research Institute (SMRI) today announced that it will ... Institute,s Stanley Center for Psychiatric Research. Launched ... the SMRI, the Stanley Center brings together scientists from ...
... Mozes HealthDay Reporter , MONDAY, May 16 (HealthDay News) ... elevate "bad" cholesterol levels, and may in fact prompt a very ... , The finding comes from a six-month examination of the ... of healthy people in England. , , "The issue is that ...
... It is important for health care providers to report health ... there is evidence of a reluctance to share patient data ... privacy and provider confidentiality. Dr. Khaled El-Emam and his research ... protocol and system that would solve this problem. The ...
... by the UK journal Reproductive Health Matters shows ... the development of a vast illegal private sector with no ... became illegal in the late 1980s the number of abortions ... trade in abortions is, however, flourishing, with abortion providers advertising ...
Cached Medicine News:Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Grant extends funding for the Broad's Stanley Center for Psychiatric Research 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 3Health News:CHEO Research Institute develops secure protocol for data disclosure 2Health News:Abortions generate $95 million a year for Polish doctors as women use illegal private sector 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: